Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor

Katherine D. Watson, Xiaowen Hu, Chun Yen Lai, Heather A. Lindfors, Dana D. Hu-Lowe, Theresa A. Tuthill, David R. Shalinsky, Katherine W. Ferrara

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r 2 = 0.86.

Original languageEnglish (US)
Pages (from-to)909-921
Number of pages13
JournalUltrasound in Medicine and Biology
Volume37
Issue number6
DOIs
StatePublished - Jun 2011

Keywords

  • AG-028262
  • CPS
  • Destruction-replenishment ultrasound
  • Dynamic contrast-enhanced MRI
  • Perfusion
  • Tumor blood flow
  • VEGF-R

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Biophysics

Fingerprint Dive into the research topics of 'Novel Ultrasound and DCE-MRI Analyses After Antiangiogenic Treatment With a Selective VEGF Receptor Inhibitor'. Together they form a unique fingerprint.

  • Cite this